CASI Pharmaceuticals Inc (CASI) FinancialsCASICASI Pharmaceuticals Inc

Evaluating the bottom line, CASI Pharmaceuticals Inc maintains a gross margin of 22.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -333.14%, while the net margin is -353.92%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CASI converts its operational activities into shareholder value.

In the context of the broader market, CASI competes directly with industry leaders such as KAPA and GTBP. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CASI's gross margin of 22.96% stands against KAPA's N/A and GTBP's N/A. Such benchmarking helps identify whether CASI Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue dropped 60.54% YoY to $3,075,000. Net income improved slightly but remains negative at -$10,883,000. EPS improved to -0.68, up 23.64% YoY, but gross margin dropped significantly to 22.96%, down 55.77% YoY. Overall, financials indicate poor performance and declining operational efficiency.